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Abstract
Background: A primary goal of acute treatment for depression is clinical remission of symptoms.
Most meta-analyses of remission rates involve randomized controlled trials (RCTs) using patients
from psychiatric settings, but most depressed patients are treated in primary care. The goal of this
study was to determine remission rates obtained in RCTs of treatment interventions for Major
Depressive Disorder (MDD) conducted in primary care settings.
Methods: Potentially relevant studies were identified using computerized and manual search
strategies up to May 2003. Criteria for inclusion included published RCTs with a clear definition of
remission using established outcome measures.
Results: A total of 13 studies (N = 3202 patients) meeting inclusion criteria were identified.
Overall remission rates for active interventions ranged between 50% and 67%, compared to 32%
for pill placebo conditions and 35% for usual care conditions.
Conclusions: Remission rates in primary care studies of depression are at least as high as for those
in psychiatric settings. It is a realistic goal for family physicians to target remission of symptoms as
an optimal outcome for treatment of depression.
Background
Major depressive disorder (MDD) is one of the most com-
mon and disabling of medical conditions [1]. The Cana-
dian Community Health Survey recently reported a one-
year prevalence rate of 4.5% for MDD, indicating that over
1.1 million Canadians suffer significant distress and
impairment in function due to depression [2]. The eco-
nomic costs of depression are estimated at over $5 billion
annually [3]. Depression is currently the fourth-ranked
medical condition contributing to global burden of dis-
ease, and is estimated to rise to second overall by the year
2010 [4].
There are many effective treatments for MDD, including
psychotherapy and antidepressants. Traditionally, efficacy
in randomized controlled trials (RCTs) for depression has
been determined on the basis of score changes in rating
scales such as the Hamilton Depression Rating Scale
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(HDRS) [5] or the Montgomery-Asberg Depression Rating
Scale (MADRS) [6]. Clinical outcome has been usually
assessed by clinical response rates, typically defined as a
50% or greater reduction from baseline scores on these
rating scales [7]. Although obtaining clinical response rep-
resents an important therapeutic milestone, it does not
necessarily indicate a complete recovery from MDD, since
many patients with clinical response will still be left with
substantial residual symptoms of depression. Studies have
shown that the presence of residual symptoms after an
episode of MDD is associated with higher risk of relapse,
recurrence, chronicity, suicide, development of cardiovas-
cular disease, and poor quality of life [8-10].
Such findings suggest that the goals of acute treatment
(approximately the first 8–12 weeks or so of treatment)
for MDD should be clinical remission, a clinical state dis-
tinguished by minimal residual symptoms, rather than
just response [11-13]. Clinical remission is typically
defined as a score within the normal range on a given out-
come measure (e.g., 17-item HDRS score of 7 or less;
MADRS score of 12 or less; Clinical Global Impression
[CGI] [14] severity score of "Normal, not at all ill"),
although there is still some uncertainty as to the validity
of these cutoff scores for symptom remission [15]. The
achievement of remission is of considerable clinical
importance as it predicts decreased risk of relapse and
greater psychosocial functioning than typically observed
in patients who have achieved clinical response alone [16-
18]. Clinical remission is now identified and promoted as
a clinical target for successful management of MDD in
many clinical practice guidelines [13,19-21].
Increasing numbers of treatment studies are now explic-
itly reporting both clinical response and remission rates in
assessment of outcome. A meta-analysis of 8 antidepres-
sant studies of venlafaxine versus selective serotonin
reuptake inhibitors [SSRIs] and placebo reported mean
remission rates of 45%, 35%, and 25%, respectively [22].
A subsequent meta-analysis of 32 RCTs comparing venla-
faxine, SSRIs and other antidepressants reported a mean
overall remission rate of 42% [23]. Finally, a meta-analy-
sis of 6 RCTs comparing antidepressants and psychother-
apy in patients with MDD reported mean remission rates
of 46% for each treatment [24].
All the studies in these systematic reviews involved
patients in psychiatric or mixed settings. However, most
people suffering from MDD will be managed in the pri-
mary care setting [25]. Approximately 5% to 10% of all
patients consulting a general practitioner have MDD, with
prevalence estimates being two to three times higher
when other depressive disorders (i.e., minor depression or
dysthymia) are included [26]. It remains unclear whether
the remission rates reported in psychiatric settings can be
extrapolated to primary care environments, although it is
of clinical importance for primary care physicians to know
whether obtaining remission is a realistic goal for their
patients. There has been a recent surge in studies assessing
a variety of treatment interventions for depression in pri-
mary care settings, making this an opportune time to per-
form a meta-analysis to address this question. Hence, the
primary objective of this study was to determine remis-
sion rates obtained in RCTs of treatment interventions for
MDD conducted in primary care settings.
Methods
Potentially relevant studies were identified using compu-
terized and manual search strategies. The computerized
search conducted in June, 2003 included the databases:
Medline, Psych Info, Embase, Biosis, Cochrane Database
of Systematic Reviews, and Cochrane Controlled Trials
Register and Current Controlled Trials (1981–May 2003).
The search terms used were 'depressive disorder' or
'depression' combined with 'primary care' and 'remission'
and/or variants. The bibliographies of relevant articles
were also manually searched. Two reviewers (MYD and
RWL) collected and independently assessed abstracts for
inclusion criteria. Disagreements were resolved with
consensus.
Inclusion criteria
Studies were included if they were RCTs with original data
comparing one or more interventions (e.g., antidepres-
sant vs. cognitive behavioral therapy) and published in
English. Only studies of predominantly adult popula-
tions, as opposed to exclusively child or elderly patient
populations, were included. Although the focus was prin-
cipally upon patients with MDD (studies primarily deal-
ing with minor depression and dysthymia were excluded),
the criteria for a diagnosis of MDD was intentionally
broad in order to capture the heterogeneity of the sample
and allow the results to be as generalizable as possible.
Included studies also had to use a standardized outcome
measure (e.g., HDRS, MADRS, Beck Depression Inventory
[BDI] [27]) and provide explicit criteria for remission.
While the definition of remission varied among the stud-
ies (Table 1), for the purpose of this meta-analysis we
accepted each study's definition of remission, which usu-
ally was a score within the normal range on the outcome
measure.
Data extraction
Two independent reviewers (MYD and EEM) extracted
data from studies using a checklist developed for this
study, with disagreements resolved by a third reviewer
(RWL). A conservative measure of remission rate was cal-
culated from each study using an intent-to-treat analysis
[28], even if this method was not used in the study. For
example, some studies calculated remission rates usingBMC Family Practice 2004, 5:19 http://www.biomedcentral.com/1471-2296/5/19
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Table 1: Summary of included studies in meta-analysis of remission rates.
Study Diagnostic 
Criteria
Follow up 
Period
Remission 
Criteria
Total N Intervention Intervention 
Remission 
Rate
Remission %
Psychological Intervention Only
Dowrick et al., 2000 
[31]
DSM-IV criteria for 
MDD or Adjustment 
Disorder
6 months No MDD 
detected by 
SCAN 
interview
425 • PST
• Usual Care
•Prevention 
course
• 58/128
• 76/189
• 44/108
• 45
• 38
• 41
Antidepressant Intervention Only
Benkert et al., 2000 
[32]
DSM-IV criteria for 
MDD and HDRS ≥ 18
6 weeks HDRS ≤ 7 275 • Mirtazapine
• Paroxetine
• 52/139
• 42/136
• 37
• 31
Patris et al.,1996 [33] DSM-IIIR criteria for 
MDD
8 weeks MADRS ≤ 12 357 • Citalopram
• Fluoxetine
• 114/173
• 110/184
• 66
• 60
Wade et al., 2002 
[34]
DSM-IV criteria for 
MDD
8 weeks MADRS ≤ 12 380 • Escitalopram
• Placebo
• 92/191
• 64/189
• 48
• 34
Psychological Intervention + Antidepressants
Chilvers et al., 2001 
[35]
Diagnosed as MDD 
by GP
12 months RDC <4, BDI 
<10, or clear 
documentation 
in GP notes that 
patient is well
103 Randomised 
only:
• 
Antidepressant
• Counselling
• 39/51
• 33/52
• 76
• 63
Mynors-Wallis et al., 
1995 [36]
Diagnosed as MDD 
by GP
12 weeks HDRS ≤ 7 or 
BDI ≤ 8
91 • PST
• Amitriptyline
• Placebo
• 18/30
• 16/31
• 8/30
• 60
• 52
• 27
Mynors-Wallis et al., 
2000 [37]
RDC criteria for 
MDD
12 months HDRS ≤ 8 151 • PST-group
•PST-RN
• 
Antidepressant
• 
PST+antidepres
sant
• 24/39
• 23/41
• 20/36
• 23/35
• 62
• 56
• 56
• 66
Schulberg et al., 1998 
[38]
DSM-IIIR criteria for 
MDD
8 months HDRS ≤ 7 184 • IPT
• Nortriptyline
• 49/93
• 52/91
• 57
• 53
Scott et al., 1992 [39] DSM-IIIR criteria for 
MDD
4 months HDRS ≤ 7 121 • CBT
• Counselling
• Amitriptyline
• Usual care
• 12/30
• 22/30
• 18/31
• 14/30
• 40
• 73
• 58
• 47
Program Interventions
Katon et al.,1999 [40] Diagnosed as MDD 
by GP
6 months Presence of 0 
or 1 SCID-
assessed 
symptoms
228 • Collaborative 
care
• Usual Care
• 50/114
• 35/114
• 44
• 31
Katzelnick et al., 2000 
[41]
Diagnosed as MDD 
by GP and HDRS ≥ 
15
12 months HDRS ≤ 7 407 • Depression 
management
• Usual care
• 92/218
• 49/189
• 42
• 26
Kutcher et al., 2002 
[42]
Diagnosed as MDD 
by GP
29 weeks 8 weeks or 
longer with 
HDRS ≤ 10
269 • Sertraline
• Sertraline + 
adherence 
program
• 84/138
• 88/131
• 61
• 67
Rost et al., 2002 [43] Diagnosed as MDD 
by GP
24 months CES-D ≤ 16 211 • Enhanced 
depression care
• Usual care
• 85/115
• 39/96
• 74
• 41
(Abbreviations: BDI – Beck Depression Inventory, CBT – Cognitive Behavioural Therapy, CES-D – Centre for Epidemiological Studies – Depression 
Scale, HDRS – Hamilton Depression Rating Scale, HSCL-D-20 – 20-item Hopkins Symptom Check List, IPT-Interpersonal Psychotherapy, MADRS – 
Montgomery-Asberg Depression Rating Scale, MDD – Major Depressive Disorder, PST – Problem Solving Therapy, PST-PC – Problem Solving 
Therapy, administered by Primary Care Physician, PST-RN – Problem Solving Therapy, administered by Registered Nurse, RDC – Research 
Diagnostic Criteria, SCAN – Schedules of Clinical Assessment in Neuropsychiatry, SCID – Structured Clinical Interview for DSM-III-R.)BMC Family Practice 2004, 5:19 http://www.biomedcentral.com/1471-2296/5/19
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only patients who returned for one follow-up visit post-
randomization, or who had completed a course of treat-
ment. The denominator used for remission rate was the
total number of patients randomized to treatment,
whether or not they were counted in the ensuing analysis.
The numerator was the number of patients in remission
reported in the study, regardless of the denominator used
in the study analysis.
The type of intervention was classified as placebo, "usual
care" by clinician (standard treatment by a patient's own
physician), psychotherapy treatment only, antidepressant
treatment only, psychotherapy plus antidepressant treat-
ment, or program intervention (e.g., collaborative care
using other health professionals; educational programs
targeted at quality improvement for prescribing practices).
Statistics
Each set of rates was pooled based on a Bayesian approach
to meta-analysis using the Fastpro software program (ver-
sion 1.7) by Eddy and Hasselblad. Readers interested in a
more detailed discussion of this approach should refer to
Eddy et al [29]. The pooled means and confidence inter-
vals were calculated using Jeffrey's prior and a random
effects model.
Results
The initial electronic and bibliographic search found 63
articles of which 47 warranted more detailed review based
on the published abstract. Of these, 34 articles were
excluded due to methodology (not RCTs, 4 studies), lack
of remission criteria (18 studies), diagnostic criteria (not
MDD, 11 studies) and age criteria (geriatric, 4 studies)
(some studies were excluded for multiple reasons, see
Additional File 1). A final count of 13 studies met the full
inclusion criteria (Table 1). In total, 3202 primary care
outpatients (75% female, 25% male) were included in the
analysis. The mean age of the participants was 32.1 years
(range 18–73 years). The average length of follow-up was
32 weeks (range 6–104 weeks).
The study interventions and methodologies were too het-
erogeneous to allow for a meaningful statistical compari-
son of results between treatments. Figure 1 shows mean
remission rates for specific interventions. Overall remis-
sion rates for active interventions, regardless of type,
ranged between 50% and 67%, compared to 32% for pill
placebo conditions and 35% for usual care conditions.
There were a sufficient number of antidepressant arms in
the studies to permit the summary of remission rates by
duration of follow-up period. For antidepressant studies
with follow-up of 6 months or less, mean remission rate
was 51.4% (95% C.I., 43.1%–59.6%); for antidepressant
studies with greater than 6 months of follow-up, mean
remission rate was 62.3% (95% C.I., 48.9%–74.8%).
Discussion
This review of research assessing remission of depressive
symptoms in primary care populations identified 13 stud-
ies meeting the inclusion criteria. Overall remission rates
(regardless of type of intervention but excluding placebo
or usual care arms) ranged between 50% and 67%. These
rates are equivalent to, or indeed greater than, those
reported in meta-analyses of studies examining pharma-
cological or psychological interventions for depression in
psychiatric populations, in which the overall remission
rates ranged between 35% and 46% [22-24]. On the one
hand, we might have predicted this finding as studies con-
ducted in primary care settings tend to include more
patients with mild to moderate depression (although we
excluded studies that focused exclusively upon minor
depression or dysthymia), whereas patients referred to
psychiatric settings are more likely to have moderate to
severe depression. Primary care treatment trials also tend
to be longer, favouring a higher remission rate; whereas
the mean follow-up period of studies included in the cur-
rent analysis was 9 months, it was only 7 weeks and 10
weeks in the two previous meta-analyses of pharmacolog-
ical interventions for MDD [22,23], and 16 weeks in the
meta-analysis of antidepressant versus psychotherapeutic
interventions [24]. Conversely, we might have predicted
that we would observe lower remission rates in the current
meta-analysis as it included a number of studies with
Remission rates for specific treatment conditions from rand- omized controlled trials (RCTs) of interventions for depres- sion in primary care settings Figure 1
Remission rates for specific treatment conditions from rand-
omized controlled trials (RCTs) of interventions for depres-
sion in primary care settings. The white lines represent the 
mean remission rates and the boxes represent the 95% con-
fidence interval. N is the number of treatment arms in the 
RCTs (Note: Psychotx = Psychotherapy, Antidepr = Antide-
pressants, pts = patients).
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more lenient exclusion criteria than typically used in psy-
chiatric clinical trials. In particular, the program interven-
tion studies tend to include more heterogeneous patient
populations as they do not routinely exclude patients with
psychiatric or medical comorbidities, factors that may
lessen the likelihood of obtaining remission of depressive
symptoms [30].
While it was not within the scope of the current study to
compare the effectiveness of different treatment interven-
tions in improving remission rates, we can report on the
trends we observed in the data. Antidepressant and psy-
chotherapy interventions delivered in isolation showed
similar remission rates (54% for both). Combination
antidepressant plus psychotherapy interventions showed
somewhat higher rates (67%), although this category
included only 1 arm with only 35 patients. Program inter-
ventions had a mean remission rate of 50%, and all treat-
ment interventions fared better than either placebo (32%)
or usual care (35%).
The studies identified in our review were quite heteroge-
neous in nature, ranging from those that looked solely at
the effects of a particular pharmacological agent, through
to complex program initiatives that incorporated a variety
of interventions at different levels of care. This heteroge-
neity limits our ability to make broad comments about
remission rates in primary care, but was not unexpected,
as we wanted to capture the diversity of treatment inter-
ventions for depression currently being tested in this set-
ting. Other potential limitations of the study include that
fact that we only assessed published studies written in
English and that we used a conservative measure of remis-
sion rate. Finally, we also used the definition of remission
as specified by each individual study. While these defini-
tions were similar to those widely used in RCTs conducted
in psychiatric settings, and thus are useful for comparison,
there is current controversy about depression scales and
which cutoff scores indicate true remission of symptoms
[15].
Conclusions
This meta-analysis serves to answer an important clinical
question about the feasibility of obtaining remission of
symptoms of MDD in primary care patients. Our results
indicate that this is a realistic goal in this population,
although further research is still required to determine
whether certain treatment modalities (or combinations of
treatment interventions) are superior to others in achiev-
ing higher remission rates. Future research should also
focus upon developing pragmatic strategies for general
practitioners to implement evidence-based guidelines
concerning the treatment of depression to clinical
remission.
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